Home/Filings/4/0000950170-24-122274
4//SEC Filing

Paulson Richard A. 4

Accession 0000950170-24-122274

CIK 0001503802other

Filed

Nov 5, 7:00 PM ET

Accepted

Nov 6, 4:06 PM ET

Size

5.3 KB

Accession

0000950170-24-122274

Insider Transaction Report

Form 4
Period: 2024-11-05
Paulson Richard A.
DirectorPresident and CEO
Transactions
  • Sale

    Common Stock

    2024-11-05$0.91/sh3,675$3,3461,131,932 total
Footnotes (2)
  • [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
  • [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.9101 to $0.9350, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Documents

1 file

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001804460

Filing Metadata

Form type
4
Filed
Nov 5, 7:00 PM ET
Accepted
Nov 6, 4:06 PM ET
Size
5.3 KB